Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 16;30(3):785–796. doi: 10.1038/s41591-024-02803-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 9 — Panel (A) shows, for each microbial SGB listed, its slopes in patients with PFS ≥ 12 months and PFS < 12 months on combination therapy, respectively. Red and blue colors indicate whether the focal SGB is increasing or decreasing in its abundance over study visits, respectively. It then shows the average difference between patients with PFS ≥ 12 and PFS < 12 months across the different study visits. Non-gray cells in the heatmap correspond to the focal SGB’s log-fold change in abundance between patients with PFS ≥ 12 and PFS < 12 months, respectively. Teal cells correspond to study visits for which the abundance of the focal SGB is higher in in patients with PFS ≥ 12 than with PFS < 12 months on combination therapy, and vice versa for brown cells (at 90% BCL). Gray cells denote differences between patients with PFS ≥ 12 and PFS < 12 months on combination therapy whose 90% CI overlapped with zero.